Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-76

I decided to give us a miss this week only to do some research in the biotech game instead.

I have caught up with a few of the message but I thought i would tag pilbars' post. What i am seeing is a great rationalisation from the big boys in their product pipeline and their choice of drugs moving forward. Donald is causing some havoc to the pricing of drugs over there and they do not like it one bit. So they have to be more shrewd. Sure some companies will pay 50 million to get a foot in the door with a potential 2 billion in future earnings. Imagine that for us. We would twenty bag on the spot. I don't see it per se, but if we get a foothold in the future prescription market, we potentially could have a couple of hundred million bucks in sales for acne alone. Nice. Possible. Maybe probable. Potentially.

I also see a lot of companies raising plenty of money on Nasdaq for a phase 3 program or further in the pipeline. I wonder at times and have mentioned whether this is Matts ultimate denouement in his decades in the biotech sector. I love this segue for matt our sly fox.